Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17285518 | 0.86 | THRB (0.39) | PKMRXFP1HPGDTHRBHDAC1 | |
| SCHEMBL30313234 | 0.84 | CES2 (0.46) | PKMRXFP1CES2CES1HPGD | |
| SCHEMBL1994723 | 0.84 | CES2 (0.46) | PKMRXFP1CES2CES1HPGD | |
| SCHEMBL1018937 | 0.83 | MEN1 (0.42) | CES2CES1HPGDHDAC1HDAC6 | |
| SCHEMBL17285516 | 0.83 | PKM (0.39) | PKMRXFP1CES2CES1THRB | |
| SCHEMBL24445654 | 0.81 | THRB (0.50) | PKMRXFP1HPGDTHRBHDAC1 | |
| SCHEMBL9789269 | 0.81 | CCNB2 (0.38) | RXFP1CES2CES1HPGDHDAC1 | |
| SCHEMBL2178523 | 0.81 | ALDH1A1 (0.38) | CES2CES1HPGDHDAC1HDAC6 | |
| SCHEMBL25046254 | 0.81 | CES2 (0.37) | CES2CES1HPGDHDAC1HDAC6 | |
| SCHEMBL24373244 | 0.79 | HDAC1 (0.38) | PKMRXFP1CES2CES1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381327-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-11-30 | — | — | US | disclosed |
| WO-2015179697-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-8188078-B2 | 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| EP-1981853-B1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LTD (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | US | disclosed |
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | ASTEX THERAPEUTICS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | ASTEX THERAPEUTICS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| WO-2008007123-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2006077419-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004243-A1 | PHARMACEUTICAL COMPOUNDS | CDK1, CDK2, CDK4 | PKM 734/4885RXFP1 4208/4885CES2 2297/4885 |
| US-20080194562-A1 | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's | CDK1, CDK3, CDK2 | PKM 350/4885RXFP1 2744/4885CES2 2972/4885 |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | PKM 589/4885RXFP1 2433/4885CES2 2851/4885 |
| US-20230381327-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | PKM 2979/4885RXFP1 1010/4885CES2 1519/4885 |
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | MET, ALK, JAK2 | PKM 1746/4885RXFP1 1314/4885CES2 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.